Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27239076 | 0.82 | KLKB1 (0.65) | KLKB1KLK1 | |
| SCHEMBL17786877 | 0.79 | KLKB1 (0.43) | KLKB1KLK1 | |
| SCHEMBL17786787 | 0.74 | KLKB1 (0.44) | KLKB1KLK1 | |
| SCHEMBL15759268 | 0.73 | KLKB1 (0.51) | KLKB1KLK1 | |
| SCHEMBL6938242 | 0.73 | CREBBP (0.56) | — | |
| SCHEMBL21491740 | 0.73 | MAPT (0.44) | KLKB1KLK1 | |
| SCHEMBL13102481 | 0.72 | KLKB1 (0.54) | KLKB1KLK1 | |
| SCHEMBL24491416 | 0.72 | CREBBP (0.36) | KLKB1KLK1 | |
| SCHEMBL17786827 | 0.72 | KLKB1 (0.43) | KLKB1KLK1 | |
| SCHEMBL23634180 | 0.71 | GABRA1 (0.40) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308125-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20240190892-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190892-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | KLKB1 1/4885KLK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.